Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)

被引：0
|
作者：
Gordon, Michael S.
Kluger, Harriet M.
Shapiro, Geoffrey
Kurzrock, Razelle
Edelman, Gerald
Samuel, Thomas A.
Moussa, Ali H.
Ramies, David A.
Laird, A. Douglas
Schimmoller, Frauke
Shen, Xiaodong
Daud, Adil
机构：
[1] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Texas Oncol, Irving, TX USA
[6] Georgia Hlth Sci Univ, Augusta, GA USA
[7] Canc Care Associates, Tulsa, OK USA
[8] Exelixis, San Francisco, CA USA
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8531
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial
    Shih, Chie-Schin
    Blakeley, Jaishri
    Clapp, D. Wade
    Armstrong, Amy E.
    Wolters, Pam
    Dombi, Eva
    Cutter, Gary
    Ullrich, Nicole J.
    Allen, Jeffrey
    Packer, Roger
    Goldman, Stewart
    Gutmann, David H.
    Plotkin, Scott
    Rosser, Tena
    Robertson, Kent
    Widemann, Brigitte
    Rhodes, Steven
    Angus, Steven
    Johnson, Gary
    Korf, Bruce
    Fisher, Michael J.
    CANCER RESEARCH, 2019, 79 (13)
  • [32] Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).
    Ratain, M. J.
    Schwartz, G. K.
    Oza, A. M.
    Rudin, C. M.
    Kaye, S. B.
    De Jonge, M. J.
    Khayat, D.
    Awada, A.
    Sawyer, M. B.
    Obel, J. C.
    Medioni, J.
    Evans, T. R. J.
    De Greve, J.
    Soetekouw, P. M.
    Baurain, J.
    O'Dwyer, P. J.
    Hartman, C.
    Poulart, V.
    Walters, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY
    Shih, Chie-Schin
    Blakely, Jaishri
    Clapp, Wade
    Wolters, Pam
    Dombi, Eva
    Cutter, Gary
    Ullrich, Nichole
    Allen, Jeffrey
    Packer, Roger
    Goldman, Stewart
    Gutmann, David
    Plotkin, Scott
    Rosser, Tena
    Robertson, Kent
    Widemann, Brigitte
    Korf, Bruce
    Fisher, Michael
    NEURO-ONCOLOGY, 2018, 20 : 142 - 142
  • [34] Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
    Luke, Jason J.
    Olson, Daniel J.
    Allred, Jacob B.
    Strand, Carrie A.
    Bao, Riyue
    Zha, Yuanyuan
    Carll, Timothy
    Labadie, Brian W.
    Bastos, Bruno R.
    Butler, Marcus O.
    Hogg, David
    Munster, Pamela N.
    Schwartz, Gary K.
    CLINICAL CANCER RESEARCH, 2020, 26 (04) : 804 - 811
  • [35] An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline
    Schoffski, Patrick
    Elisei, Rossella
    Mueller, Stefan
    Brose, Marcia S.
    Shah, Manisha H.
    Licitra, Lisa F.
    Jarzab, Barbara
    Medvedev, Viktor
    Kreissl, Michael
    Niederle, Bruno
    Cohen, Ezra E. W.
    Wirth, Lori J.
    Ali, Haythem Y.
    Hessel, Colin
    Yaron, Yifah
    Ball, Douglas Wilmot
    Nelkin, Barry
    Sherman, Steven I.
    Schlumberger, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] BRIVANIB (B) IN ADVANCED OVARIAN CANCER (OC): SUBSET RESULTS OF A PHASE 2 RANDOMIZED DISCONTINUATION TRIAL (RDT)
    Kaye, S. B.
    Siu, L. L.
    Jassem, J.
    Medioni, J.
    Soetekouw, P. M. M. B.
    Slater, S.
    Rudin, C. M.
    Schwartz, G. K.
    De Jonge, M.
    O'Dwyer, P.
    Baudelet, C.
    Chen, A.
    Ratain, M. J.
    ANNALS OF ONCOLOGY, 2012, 23 : 319 - 319
  • [37] Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT)
    Ratain, MJ
    Flaherty, KT
    Stadler, WM
    O'Dwyer, P
    Kaye, S
    Xiong, H
    Patnaik, A
    Gore, M
    Lee, RJ
    Eisen, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 382S - 382S
  • [38] Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma
    Hellerstedt, Beth A.
    Vogelzang, Nicholas J.
    Kluger, Harriet M.
    Yasenchak, Christopher A.
    Aftab, Dana T.
    Ramies, David A.
    Gordon, Michael S.
    Lara, Primo, Jr.
    CLINICAL LUNG CANCER, 2019, 20 (02) : 74 - +
  • [39] Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RI C): Subgroup analysis from a phase II randomized discontinuation trial (RDT)
    Bhargava, P.
    Esteves, B.
    Al-Adhami, M.
    Nosov, D.
    Lipatov, O. N.
    Lyulko, A. K.
    Anischenko, A. A.
    Chacko, R. T.
    Doval, D.
    Slichenmyer, W. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children's Oncology Group phase I consortium trial.
    Chuk, Meredith K.
    Widemann, Brigitte C.
    Ahern, Charlotte H.
    Reid, Joel M.
    Kim, AeRang
    Wright, John Joseph
    Lodish, Maya
    Fox, Elizabeth
    Weigel, Brenda
    Blaney, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345